PS93. Repeated Low-Grade Inflammation Increases the Risk of Antidepressant-Resistant Depression: A Nationwide Population-Based Cohort Study

Background: Some clinical studies have reported the alteration of serum brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) level before and after the antidepressant treatments in patients with major depressive disorder (MDD). We evaluated serum BDNF and GDNF levels before and after the 12-week antidepressant treatments in MDD outpatients. Methods: Serum BDNF and GDNF levels were measured in 28 MDD outpatients. The severity of depression was measured with the Hamilton Depression Rating Scale (HAMD). Results: Serum BDNF and GDNF levels were significantly decreased after the 12-week antidepressant treatments with comparison of those before the treatments (p<0.05). The baseline serum BDNF and GDNF levels in the remission group were higher than in non-remission group, but that were not statistically significant. Conclusions: Our study revealed a reduction of serum BDNF and GDNF levels after the antidepressant treatments in MDD outpatients.